Clinical trial · Observational
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
NCT04324164CI-TRIAL-00085098recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EGFR-TKI | Drug | — | UNRESOLVED |
| Third-generation EGFR-TKI | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (7)
- label
- Cohort 1 Uncommon EGFR exon 19del
- description
- patients with uncommon EGFR exon 19del
- interventionNames
- Drug: Third-generation EGFR-TKI
- label
- Cohort 2 EGFR exon 19delins
- description
- patients with EGFR exon 19delins
- interventionNames
- Drug: Third-generation EGFR-TKI
- label
- Cohort 3 EGFR exon 18del
- description
- patients with EGFR exon 18del
- interventionNames
- Drug: EGFR-TKI
- label
- Cohort 4 Common Uncommon Point Mutations
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * Uncommon EGFR Mutant Advanced NSCLC Exclusion Criteria: * Patients with contraindication of chemotherapy * Pregnant or breast feeding women
References
Publications (0)
Data not yet available
No reference posted for this study.